Zhong Guo Ji Jin Bao·2025-12-10 14:56Core Viewpoint - Xinfeng Pharmaceutical is facing legal challenges as it has been prosecuted for alleged unit bribery, which may adversely affect its brand reputation and future business development [1][3][5]. Group 1: Legal Issues - On December 10, Xinfeng Pharmaceutical announced that it has been prosecuted for alleged unit bribery, with the prosecution materials received from the supervisory committee [1][3]. - The company is currently in the prosecution review stage and has appointed defense lawyers to handle the case [5]. Group 2: Stock Market Reaction - Following the announcement of the legal issues, Xinfeng Pharmaceutical's stock price experienced a significant increase, reaching a limit-up of 4.15 yuan per share, with a total market capitalization of 8.067 billion yuan [2]. Group 3: Company Performance - For the first three quarters of the year, Xinfeng Pharmaceutical reported a revenue of 4.266 billion yuan, a year-on-year decrease of 6.55%, and a net profit attributable to shareholders of 152 million yuan, down 13.74% year-on-year [8]. - The company's financial performance has been unstable, with a projected decline of over 60% in net profit attributable to shareholders for 2024 [8].